Vitrafy Life Sciences (VFY) H2 2026 earnings summary

Executive summary

• Achieved transformational progress, moving from early-stage partnerships to commercial momentum and product availability in market, including successful commercial partnerships and U.S. market establishment.

• Delivered Guardion freezing device and LifeChain software, with regulatory approval processes underway.

• Expanded from a single military partnership to multiple agreements in both military and civilian health sectors, including major U.S. blood centers.

• Secured a global partnership in animal reproduction, generating recurring revenue and expanding international reach.

• Established a structured U.S. team and operations, with leadership relocating to the U.S. to drive further growth.

Financial highlights

• Revenue exceeded AUD 1 million, driven by strong growth in animal reproduction and aquaculture segments; animal health revenue reached $169k, up 159% year-over-year.

• Total cash and term deposits at $41.2m as of June 2026, following a $30m capital raise.

• Operating loss of $16.8m for FY26, improved from $14.6m loss in FY25.

• Grant income of $3.45m received, with an additional $0.4m expected in early FY27.

• Consulting and materials costs totaled approximately AUD 6 million, reflecting investment in product development.

Outlook and guidance

• Focus on expanding U.S. civilian and military blood market partnerships, aiming to capture a larger share of the network.

• FDA Guardion device registration and broad-scale adoption targeted for FY27.

• Anticipates first commercial revenue from cell and gene therapy contracts in 1H FY27.

• Continued ramp-up of U.S. manufacturing and operational capabilities to meet anticipated demand.

• Ongoing evaluation of capital needs, with sufficient cash for near-term growth and potential for future debt/equity mix.